<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654560</url>
  </required_header>
  <id_info>
    <org_study_id>UHP001</org_study_id>
    <nct_id>NCT03654560</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting</brief_title>
  <official_title>Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Health Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Health Products, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess efficacy and safety of HemoStyp as an adjunct for
      management of secondary hemostasis in the operative setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-inferiority, multi-center, randomized, open-label trial to
      compare HemoStyp with SurgicelÂ® in the management of bleeding during surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Non-inferiority of HemoStyp versus Surgicel measured using time to hemostasis from start of study treatment at target bleeding site until 10 minutes after treatment initiation.</measure>
    <time_frame>10 minutes</time_frame>
    <description>Time to hemostasis from start of study treatment at target bleeding site until 10 minutes after treatment initiation. The non-inferiority of HemoStyp versus Surgicel will be evaluated. If the criteria for non-inferiority are satisfied, a superiority analysis will be performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving Hemostasis between 2 minutes and 10 minutes</measure>
    <time_frame>Between 2 minutes and 10 minutes</time_frame>
    <description>Percentage of subjects achieving hemostasis at the target bleeding site at 2 minutes, 5 minutes and 10 minutes following the start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects Achieving Intraoperative Hemostasis at the Target Bleeding Site</measure>
    <time_frame>Intraoperative period</time_frame>
    <description>Percentage of subjects with intraoperative hemostasis at the target bleeding site during the intraoperative period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects with intraoperative re-bleeding from the target bleeding site</measure>
    <time_frame>Intraoperative period post hemostasis</time_frame>
    <description>Percentage of subjects with intraoperative re-bleeding from the target bleeding site post hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of subjects requiring surgical re-exploration up to 30 days after surgery for re-bleeding from the target bleeding site</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative re-bleeding from the target bleeding site requiring surgical re exploration up to 30 days after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Hemostasis</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>HemoStyp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgicel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HemoStyp</intervention_name>
    <description>During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.</description>
    <arm_group_label>HemoStyp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgicel</intervention_name>
    <description>During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.</description>
    <arm_group_label>Surgicel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Elective procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular
             surgery);

          2. At time of surgery has mild to moderate soft tissue, vascular or parenchymal bleeding
             present at target bleeding site after primary standard conventional surgical
             hemostatic methods are proven to be ineffective or impractical;

          3. Ages: Pediatric subjects 2 years to 17 years of age and adult subjects 18 years of age
             or older; and

          4. Subjects or parent or legal guardian of the subject who are willing and able to sign
             consent.

        Exclusion Criteria:

          1. Physical or psychological condition which would impair study participation;

          2. Indications for emergency surgery;

          3. Pre-operative laboratory findings of a hematologic disorder;

          4. Subjects with history of moderate to severe allergies;

          5. Subjects undergoing minimally invasive laparoscopic surgery;

          6. Subjects who will require platelet or fresh frozen plasma transfusion during surgery;

          7. Subjects who are pregnant or breast-feeding at the time of surgery; or

          8. Subjects on P2Y12 platelet inhibitor (Plavix) less than 5 days prior to surgery,
             warfarin or Xa inhibitors not withheld per standard protocols for the management of
             anticoagulants pre-operatively.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Raymond Schaerf</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

